Quantification of the degradation products of sevoflurane using four brands of CO₂ absorbent in a standard anesthetic circuit

Abstract

Purpose. CO₂ absorbents convert sevoflurane to fluoromethyl-2,2-difluoro-1-(trifluoromethyl) vinyl ether (compound A), whose toxicity in rats raises concern regarding the safety of sevoflurane in a low-flow system. The type of CO₂ absorbent is one of factors that affect compound A concentration in the anesthetic circuit. The aim of the present study was to investigate the concentration of compound A in an anesthetic model circuit following the use of different brands of soda lime and Baralyme.

Methods. We measured the concentrations of compound A in four different brands of CO₂ absorbent using a low-flow (1 l·min⁻¹ fresh gas) model circuit in which 2% sevoflurane was circulated. Sodasorb II, Baralyme, Sofnolime and Wakolime-A were used as CO₂ absorbents. The concentration of compound A was measured hourly, and the temperature of the CO₂ absorbent was monitored.

Results. The maximum concentration of compound A in the circuit was highest for Baralyme (25.5 ± 0.6 ppm) (mean ± SD), followed by Sodasorb II (18.9 ± 1.6 ppm), Wakolime-A (16.1 ± 0.7 ppm), and Sofnolime (15.8 ± 1.4 ppm). The maximum temperature was 50.8 ± 1.3°C for Baralyme, 48.8 ± 1.3°C for Wakolime-A, 47.0 ± 1.4°C for Sodasorb II, and 43.5 ± 3.9°C for Sofnolime.

Conclusion. The relative concentrations of compound A in the low-flow circuit were Baralyme > Sodasorb II > Wakolime-A = Sofnolime.